title: Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment.
abstract: In a double-blind placebo-controlled study, the effects of Actovegin on cognitive event-related potentials were studied in 18 age-associated memory impairment (AAMI) patients. Actovegin is a protein-free metabolically active hemoderivative improving oxygen and glucose utilization. Each patient was treated, in randomized order, for 2 weeks with 250 ml 20% Actovegin and 250 ml placebo daily with an interval of 3 weeks in between. Psychophysiological tests were carried out by means of the Viennese Psychophysiological Test System (VPTS) before as well as 5 h after the administration of one single infusion on day 1 (acute effect), before (subacute effect) as well as after one additional superimposed infusion on day 15 (superimposed effect). There was no effect on earlier stages of information processing measured by N1 and P2 component of nontarget ERP nor on ERP latencies. However, P300 amplitude increased after acute, subacute as well as superimposed infusion of Actovegin as compared to placebo, confirming the hypothesis that nootropic drugs may influence the P300 amplitude in the sense of an improved availability of cognitive processing resources. This increase of P300 amplitude (up to 4.8 microV), seen specifically in central and parietal regions, proved to be significant in a confirmatory test.
authors: Department of Psychiatry, University of Vienna, Austria.
authors: H V
authors: HV
authors: Semlitsch
authors: P
authors: P
authors: Anderer
authors: B
authors: B
authors: Saletu
authors: I
authors: I
authors: Hochmayer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000523:psychology*; D001931:Brain Mapping; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006418:Heme / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008569:Memory Disorders / Q000503:physiopathology* / Q000523:psychology; D008875:Middle Aged; D011581:Psychological Tests; D011930:Reaction Time
chemical_list: D006418:Heme; C015646:Actovegin